We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.7%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$286M
AUM Growth
-$32.2M
Cap. Flow
+$12.1M
Cap. Flow %
4.24%
Top 10 Hldgs %
59.29%
Holding
46
New
14
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$12.2M
2
EPZM
Epizyme, Inc
EPZM
+$9.1M
3
AIMT
Aimmune Therapeutics
AIMT
+$8.13M
4
XLRN
Acceleron Pharma
XLRN
+$7.86M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$6.69M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$7.5M
2
KYNB
Kyntra Bio
KYNB
+$7.03M
3
TPST icon
Tempest Therapeutics
TPST
+$4.15M
4
ATYR
aTyr Pharma
ATYR
+$3.88M
5
GNVC
GenVec, Inc.
GNVC
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 76.37%
2 Miscellaneous 23.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$682M
$22.6M 7.88%
2,461,332
+1,480,424
+151% +$12.2M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$20.3M 7.11%
500,757
-218,243
-30% -$7.5M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$19.4M 6.77%
1,598,900
+900,000
+129% +$9.1M
KYNB
4
Kyntra Bio
KYNB
$32.5M
$18.4M 6.43%
34,550
-14,109
-29% -$7.03M
TVTX icon
5
Travere Therapeutics
TVTX
$6.19B
$16.7M 5.85%
1,225,084
+700
+0.1% +$10.6K
XNTK icon
6
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$15.4M 5.36%
+297,200
New +$14.6M
CYTK icon
7
Cytokinetics
CYTK
$10B
$14.5M 5.06%
2,052,800
+634,100
+45% +$4.63M
GILD icon
8
CALL
Gilead Sciences
GILD
$181B
$13.8M 4.81%
150,000
+138,200
+1,171% +$12.5M
ASMB icon
9
Assembly Biosciences
ASMB
$694M
$10.5M 3.68%
174,859
– –
CPXX
10
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$10.5M 3.66%
+950,000
New +$3.11M
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$10.3M 3.6%
246,691
+79,330
+47% +$3.68M
KURA icon
12
Kura Oncology
KURA
$1.13B
$9.98M 3.49%
2,465,286
+15,286
+0.6% +$72.5K
COLL icon
13
Collegium Pharmaceutical
COLL
$786M
$8.59M 3%
473,123
+8,005
+2% +$146K
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$7.13M 2.49%
+270,289
New +$7.86M
AIMT
15
DELISTED
Aimmune Therapeutics
AIMT
$7.07M 2.47%
+521,366
New +$8.13M
ENTA icon
16
Enanta Pharmaceuticals
ENTA
$396M
$7.06M 2.47%
+240,383
New +$6.69M
KITE
17
DELISTED
Kite Pharma, Inc.
KITE
$6.89M 2.41%
150,000
-16,000
-10% -$775K
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.74B
$6.8M 2.38%
+510,829
New +$6.42M
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$6.34M 2.22%
2,831
-524
-16% -$1.13M
DCOY
20
Decoy Therapeutics
DCOY
$1.9M
$6.32M 2.21%
1
– –
KIN
21
DELISTED
Kindred Biosciences, Inc.
KIN
$4.94M 1.73%
1,432,765
– –
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
$4.11M 1.44%
+150,308
New +$3.15M
IRWD icon
23
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$3.28M 1.15%
+358,200
New +$2.95M
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.18M 1.11%
6,318
– –
EDIT icon
25
Editas Medicine
EDIT
$485M
$3.04M 1.06%
+87,921
New +$2.31M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2016 Portfolio in Review

As of Q1 2016, EcoR1 Capital held 46 positions worth $286M, down 10% from $318M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $12.1M of net new capital in Q1 2016, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Aimmune Therapeutics: 521,366 shares worth $7.07M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $7.5M trimmed.

  • EcoR1 Capital's largest Q1 2016 buy was Aimmune Therapeutics: 521,366 shares worth $7.07M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q1 2016, an estimated $12.2M increase.
  • EcoR1 Capital's biggest Q1 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $7.5M.
  • EcoR1 Capital fully exited Tempest Therapeutics in Q1 2016, selling an estimated $4.15M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $286M portfolio in Q1 2016.
  • EcoR1 Capital opened 14 new positions and closed 9 in Q1 2016.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $286M.

Based on EcoR1 Capital's 13F filing for Q1 2016, filed 16 May 2016.